Alpine Global Management’s Standard BioTools LAB Stock Holding History

Alpine Global Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-293,706	Closed	-$520K	–	309
2024 Q2	$520K	Buy	+293,706	New	+$718K	0.09%	171
2022 Q4	–	Sell	-13,475	Closed	-$15K	–	513
2022 Q3	$15K	Hold	13,475	–	–	﹤0.01%	170
2022 Q2	$22K	Hold	13,475	–	–	0.01%	194
2022 Q1	$48	Sell	13,475 -11,858	-47%	-$41K	0.01%	314
2021 Q4	$99K	Buy	+25,333	New	+$119K	0.01%	643
2021 Q1	–	Sell	-20,982	Closed	-$126K	–	344
2020 Q4	$126K	Buy	+20,982	New	+$138K	0.03%	147

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpine Global Management's LAB Position: Q3 2024 in Review

Alpine Global Management sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 293,706 shares — an estimated $520K sold.

Alpine Global Management first reported a position in LAB in Q4 2020 and held it in 6 quarters. The position peaked at $520K in Q2 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

Alpine Global Management reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
Alpine Global Management sold 293,706 Standard BioTools shares in Q3 2024, an estimated $520K.
Alpine Global Management first reported a position in Standard BioTools in Q4 2020 and held it in 6 quarters.
Alpine Global Management's Standard BioTools position peaked at $520K in Q2 2024.
141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.